Vaccine Based on Recombinant Fusion Protein Combining Hepatitis B Virus PreS with SARS-CoV-2 Wild-Type- and Omicron-Derived Receptor Binding Domain Strongly Induces Omicron-Neutralizing Antibodies in a Murine Model

Vaccine Based on Recombinant Fusion Protein Combining Hepatitis B Virus PreS with SARS-CoV-2 Wild-Type- and Omicron-Derived Receptor Binding Domain Strongly Induces Omicron-Neutralizing Antibodies in a Murine Model

Background: COVID-19, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a recurrent endemic disease affecting the whole world. Since November 2021, Omicron and its subvariants have dominated in the spread of the disease. In order to prevent severe courses of dise...

Full description

Bibliographic Details
Main Authors: Pia Gattinger, Bernhard Kratzer, Al Nasar Ahmed Sehgal, Anna Ohradanova-Repic, Laura Gebetsberger, Gabor Tajti, Margarete Focke-Tejkl, Mirjam Schaar, Verena Fuhrmann, Lukas Petrowitsch, Walter Keller, Sandra Högler, Hannes Stockinger, Winfried F. Pickl, Rudolf Valenta
Format: Article
Language:English
Published: MDPI AG 2024-02-01
Series:Vaccines
Subjects:
SARS-CoV-2
COVID-19
Omicron
vaccine
neutralizing antibodies
Online Access:https://www.mdpi.com/2076-393X/12/3/229

Internet

https://www.mdpi.com/2076-393X/12/3/229

Similar Items